Glioma Associated Stem Cells (GASCs) represent a population of nontumorigenic
multipotent stem cells hosted in the microenvironment of human gliomas. In vitro,
these cells are able, through the release of exosomes, to increase the biological
aggressiveness of glioma-initiating cells. The clinical importance of this finding is supported
by the strong prognostic value associated with the GASCs surface immunophenotype thus
suggesting that this patient-based approach can provide a groundbreaking method to predict
prognosis and to exploit novel strategies that target the tumor stroma
